{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:18:28Z","timestamp":1772842708693,"version":"3.50.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005856","name":"Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa","doi-asserted-by":"publisher","award":["2121.00895.CEECIND"],"award-info":[{"award-number":["2121.00895.CEECIND"]}],"id":[{"id":"10.13039\/501100005856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005856","name":"Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa","doi-asserted-by":"publisher","award":["PTDC\/BTM-MAT\/2472\/2021"],"award-info":[{"award-number":["PTDC\/BTM-MAT\/2472\/2021"]}],"id":[{"id":"10.13039\/501100005856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005856","name":"Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa","doi-asserted-by":"publisher","award":["PTDC\/QUI-OUT\/3989\/2021"],"award-info":[{"award-number":["PTDC\/QUI-OUT\/3989\/2021"]}],"id":[{"id":"10.13039\/501100005856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005856","name":"Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa","doi-asserted-by":"publisher","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}],"id":[{"id":"10.13039\/501100005856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005856","name":"Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa","doi-asserted-by":"publisher","award":["SFRH\/BD\/131468\/2017"],"award-info":[{"award-number":["SFRH\/BD\/131468\/2017"]}],"id":[{"id":"10.13039\/501100005856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cancer is a major public health problem with over 19 million cases reported in 2020. Similarly to humans, dogs are also largely affected by cancer, with non-Hodgkin's lymphoma (NHL) among the most common cancers in both species. Comparative medicine has the potential to accelerate the development of new therapeutic options in oncology by leveraging commonalities between diseases affecting both humans and animals. Within this context, in the present study, we investigated the potential of panobinostat (Pan)-loaded folate-targeted PEGylated liposomes (FA-PEG-Pan-Lip) for the treatment of canine B-cell lymphoma, while contributing to new perspectives in comparative oncology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>Two formulations were developed, namely: PEG-Pan-Lip and FA-PEG-Pan-Lip. Firstly, folate receptor expression in the CLBL-1 canine B-cell lymphoma cell line was assessed. After confirming receptor expression, both Pan-loaded formulations (PEG-Pan-Lip, FA-PEG-Pan-Lip) demonstrated dose-dependent inhibitory effects on CLBL-1 cell proliferation. The FA-PEG-Pan-Lip formulation (IC<jats:sub>50<\/jats:sub> = 10.9 \u00b1 0.03 nM) showed higher cytotoxicity than the non-targeted PEG-Pan-Lip formulation (IC<jats:sub>50<\/jats:sub> = 12.9 \u00b1 0.03 nM) and the free panobinostat (Pan) compound (IC<jats:sub>50<\/jats:sub> = 18.32\u00b10.03 nM). Moreover, mechanistically, both Pan-containing formulations induced acetylation of H3 histone and apoptosis. Flow cytometry and immunofluorescence analysis of intracellular uptake of rhodamine-labeled liposome formulations in CLBL-1 cells confirmed cellular internalization of PEG-Lip and FA-PEG-Lip formulations and higher uptake profile for the latter. Biodistribution studies of both radiolabeled formulations in CD1 and SCID mice revealed a rapid clearance from the major organs and a 1.6-fold enhancement of tumor uptake at 24 h for <jats:sup>111<\/jats:sup>In-FA-PEG-Pan-Lip (2.2 \u00b1 0.1 %ID\/g of tumor) compared to <jats:sup>111<\/jats:sup>In-PEG-Pan-Lip formulation (1.2\u00b10.2 %ID\/g of tumor).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In summary, our results provide new data validating Pan-loaded folate liposomes as a promising targeted drug delivery system for the treatment of canine B-cell lymphoma and open innovative perspectives for comparative oncology.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fvets.2023.1236136","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T05:51:56Z","timestamp":1693461116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Panobinostat-loaded folate targeted liposomes as a promising drug delivery system for treatment of canine B-cell lymphoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Ana S.","family":"Andr\u00e9","sequence":"first","affiliation":[]},{"given":"Joana N. R.","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Sandra I.","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Leonardo","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Nogueira","sequence":"additional","affiliation":[]},{"given":"Joana D.","family":"Amaral","sequence":"additional","affiliation":[]},{"given":"C\u00e9lia","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Lurdes","family":"Gano","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o D. G.","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Cavaco","sequence":"additional","affiliation":[]},{"given":"Vera","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Castanho","sequence":"additional","affiliation":[]},{"given":"Cec\u00edlia M. P.","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Maria Manuela","family":"Gaspar","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Frederico","family":"Aires-da-Silva","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-animal-022114-110911","article-title":"Dogs as a model for cancer","volume":"4","author":"Gardner","year":"2016","journal-title":"Annu Rev Anim Biosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"20140231","DOI":"10.1098\/rstb.2014.0231","article-title":"Comparative oncology: what dogs and other species can teach us about humans with cancer","volume":"370","author":"Schiffman","year":"2015","journal-title":"Philos Trans R Soc Lond, B, Biol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"k3204","DOI":"10.1136\/bmj.k3204","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"Bowzyk Al-Naeeb","year":"2018","journal-title":"BMJ."},{"key":"B6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","article-title":"Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications","volume":"159","author":"Ito","year":"2014","journal-title":"Vet Immunol and Immunopathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.mayocp.2015.04.025","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/pharmaceutics13101598","article-title":"Highly specific blood-brain barrier transmigrating single-domain antibodies selected by an in vivo phage display screening","volume":"13","author":"Aguiar","year":"2021","journal-title":"Pharmaceutics."},{"key":"B9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2174\/1389201016666150118135107","article-title":"Folate receptor targeted liposomes encapsulating anti-cancer drugs","volume":"16","author":"Chaudhury","year":"2015","journal-title":"Curr Pharm Biotechnol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1089\/jamp.2011.0928","article-title":"Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats","volume":"25","author":"Gaspar","year":"2012","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-642-00477-3_1","article-title":"Passive and active drug targeting: drug delivery to tumors as an example","volume":"2010","author":"Torchilin","year":"2010","journal-title":"Handb Exp Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrc2273","article-title":"Translation of new cancer treatments from pet dogs to humans","volume":"8","author":"Paoloni","year":"2008","journal-title":"Nat Rev Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene."},{"key":"B15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","article-title":"Histone deacetylase inhibitors in hematological malignancies and solid tumors","volume":"38","author":"Chun","year":"2015","journal-title":"Arch Pharm Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","article-title":"Emerging epigenetic-modulating therapies in lymphoma","volume":"16","author":"Sermer","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1517\/13543784.2011.594437","article-title":"Romidepsin: a novel histone deacetylase inhibitor for cancer","volume":"20","author":"Bertino","year":"2011","journal-title":"Expert Opin Investig Drugs."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist."},{"key":"B20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"28586","DOI":"10.18632\/oncotarget.25580","article-title":"The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma","volume":"9","author":"Dias","year":"2018","journal-title":"Oncotarget."},{"key":"B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/pharmaceutics11010022","article-title":"Current trends in cancer nanotheranostics: metallic, polymeric, and lipid-based systems","volume":"11","author":"Co","year":"2019","journal-title":"Pharmaceutics."},{"key":"B23","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.medidd.2020.100040","article-title":"Nanomaterials as potential transporters of HDAC inhibitors","volume":"6","author":"De Souza","year":"2020","journal-title":"Med Drug Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3390\/molecules26072047","article-title":"Liposomes as antibiotic delivery systems: a promising nanotechnological strategy against antimicrobial resistance","volume":"26","author":"Ferreira","year":"2021","journal-title":"Molecules."},{"key":"B25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/biomedicines11020435","article-title":"Advancing medicine with lipid-based nanosystems-the successful case of liposomes","volume":"11","author":"Luiz","year":"2023","journal-title":"Biomedicines."},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics."},{"key":"B27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2147\/IJN.S26172","article-title":"Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft","volume":"7","author":"Chaudhury","year":"2012","journal-title":"Int J Nanomedicine."},{"key":"B29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2006.10.018","article-title":"Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis","volume":"117","author":"Gaspar","year":"2007","journal-title":"J Control Rel."},{"key":"B30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2217\/nnm-2018-0388","article-title":"Copper complex nanoformulations featuring highly promising therapeutic potential in murine melanoma models","volume":"14","author":"Pinho","year":"2019","journal-title":"Nanomedicine."},{"key":"B31","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","article-title":"Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma","volume":"34","author":"R\u00fctgen","year":"2010","journal-title":"Leuk Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e40078","DOI":"10.1371\/journal.pone.0040078","article-title":"Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine b-cell lymphoma in a murine in vivo model","volume":"7","author":"R\u00fctgen","year":"2012","journal-title":"PLoS ONE."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e45468","DOI":"10.1371\/journal.pone.0045468","article-title":"Pharmacokinetic analysis of 111In-labeled liposomal doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound","volume":"7","author":"Yang","year":"2012","journal-title":"PLoS ONE."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0208147","DOI":"10.1371\/journal.pone.0208147","article-title":"Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies","volume":"13","author":"Dias","year":"2018","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"114021","DOI":"10.1016\/j.biopha.2022.114021","article-title":"Preclinical validation of a new hybrid molecule loaded in liposomes for melanoma management","volume":"157","author":"Pinho","year":"2023","journal-title":"Biomed Pharmacother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12645-019-0055-y","article-title":"Nanomedicine review: clinical developments in liposomal applications","volume":"10","author":"Beltr\u00e1n-Gracia","year":"2019","journal-title":"Cancer Nanotechnol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int J Nanomedicine."},{"key":"B39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae-the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"Review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules."},{"key":"B41","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1939-1676.2007.tb01958.x","article-title":"Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma","volume":"21","author":"Sorenmo","year":"2007","journal-title":"J Vet Intern Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1476-5829.2011.00266.x","article-title":"A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma","volume":"9","author":"Teske","year":"2011","journal-title":"Vet Comp Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s002800050591","article-title":"Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors","volume":"39","author":"Vail","year":"1997","journal-title":"Cancer Chemother Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-06-0226","article-title":"Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors","volume":"12","author":"Hauck","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/pharmaceutics11080381","article-title":"Formulation strategies for folate-targeted liposomes and their biomedical applications","volume":"11","author":"Kumar","year":"2019","journal-title":"Pharmaceutics."},{"key":"B46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-009-1132-4","article-title":"Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models","volume":"66","author":"Gabizon","year":"2010","journal-title":"Cancer Chemother Pharmacol."},{"key":"B47","first-page":"6551","article-title":"In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice","volume":"9","author":"Gabizon","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/1535-7163.MCT-05-0543","article-title":"Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors","volume":"5","author":"Shmeeda","year":"2006","journal-title":"Mol Cancer Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2147\/DDDT.S152420","article-title":"Lymphoma-targeted treatment using a folic acid-decorated vincristine-loaded drug delivery system","volume":"12","author":"Qiu","year":"2018","journal-title":"Drug Des Devel Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.nano.2015.06.008","article-title":"Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems","volume":"11","author":"Gaspar","year":"2015","journal-title":"Nanomedicine."},{"key":"B51","article-title":"(Chezy) \u201cDoxil\u00ae\u2013the first FDA-approved nano-drug: from an idea to a product","author":"Barenholz","year":"2021"},{"key":"B52","doi-asserted-by":"publisher","first-page":"705886","DOI":"10.3389\/fbioe.2021.705886","article-title":"Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol","volume":"9","author":"Nakhaei","year":"2021","journal-title":"Front Bioeng Biotechnol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1073\/pnas.1324135111","article-title":"Remote loading of preencapsulated drugs into stealth liposomes","volume":"111","author":"Sur","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B54","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene."},{"key":"B55","doi-asserted-by":"publisher","first-page":"16635","DOI":"10.1038\/s41598-017-16653-2","article-title":"Caspase-3\/-7-specific metabolic precursor for bioorthogonal tracking of tumor apoptosis","volume":"7","author":"Shim","year":"2017","journal-title":"Sci Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/pharmaceutics6010137","article-title":"Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology","volume":"6","author":"Ait-Oudhia","year":"2014","journal-title":"Pharmaceutics."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2023.1236136\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T05:52:01Z","timestamp":1693461121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2023.1236136\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":56,"alternative-id":["10.3389\/fvets.2023.1236136"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2023.1236136","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]},"article-number":"1236136"}}